Uday Pratap

Dr. Uday Pratap


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2021 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Open access
DBDarrell Brann
Darrell Brann
YLYujiao Lu
Yujiao Lu
JWJing Wang
Jing Wang
QZQuanguang Zhang
Quanguang Zhang
RTRoshni Thakkar
Roshni Thakkar
RVRatna Vadlamudi
Ratna Vadlamudi
Although classically known as an endocrine signal produced by the ovary, 17β-estradiol (E2) is also a neurosteroid produced in neurons and astrocytes in the brain of many different species. In this review, we provide a comprehensive overview of the localization, regulation, sex differences, and physiological/pathological roles of brain-derived E2 (BDE2). Much of what we know regarding the functional roles of BDE2 has come from studies using specific inhibitors of the E2 synthesis enzyme, aromatase, as well as the recent development of conditional forebrain neuron-specific and astrocyte-specific aromatase knockout mouse models. The evidence from these studies support a critical role for neuron-derived E2 (NDE2) in the regulation of synaptic plasticity, memory, socio-sexual behavior, sexual differentiation, reproduction, injury-induced reactive gliosis, and neuroprotection. Furthermore, we review evidence that astrocyte-derived E2 (ADE2) is induced following brain injury/ischemia, and plays a key role in reactive gliosis, neuroprotection, and cognitive preservation. Finally, we conclude by discussing the key controversies and challenges in this area, as well as potential future directions for the field.

1 August 2019 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
SVSuryavathi Viswanadhapalli
Suryavathi Viswanadhapalli
YLYiliao Luo
Yiliao Luo
GSGangadhara R. Sareddy
Gangadhara R. Sareddy
BSBindu Santhamma
Bindu Santhamma
MZMei Zhou
Mei Zhou
RVRatna Vadlamudi
Ratna Vadlamudi
Leukemia inhibitory factor receptor (LIFR) and its ligand LIF play a critical role in cancer progression, metastasis, stem cell maintenance, and therapy resistance. Here, we describe a rationally designed first-in-class inhibitor of LIFR, EC359, which directly interacts with LIFR to effectively block LIF/LIFR interactions. EC359 treatment exhibits antiproliferative effects, reduces invasiveness and stemness, and promotes apoptosis in triple-negative breast cancer (TNBC) cell lines. The activity of EC359 is dependent on LIF and LIFR expression, and treatment with EC359 attenuated the activation of LIF/LIFR-driven pathways, including STAT3, mTOR, and AKT. Concomitantly, EC359 was also effective in blocking signaling by other LIFR ligands (CTF1, CNTF, and OSM) that interact at LIF/LIFR interface. EC359 significantly reduced tumor progression in TNBC xenografts and patient-derived xenografts (PDX), and reduced proliferation in patient-derived primary TNBC explants. EC359 exhibits distinct pharmacologic advantages, including oral bioavailability, and in vivo stability. Collectively, these data support EC359 as a novel targeted therapeutic that inhibits LIFR oncogenic signaling. See related commentary by Shi et al., p. 1337

18 January 2023 in Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
SASalvador Alejo
Salvador Alejo
BPBridgitte E Palacios
Bridgitte E Palacios
PVPrabhakar Pitta Venkata
Prabhakar Pitta Venkata
YHYi He
Yi He
Wenjing LiWenjing Li
Wenjing Li
GSGangadhara R Sareddy
Gangadhara R Sareddy
Efficient DNA repair in response to standard chemo and radiation therapies often contribute to GBM therapy resistance. Understanding the mechanisms of therapy resistance and identifying the drugs that enhance the therapeutic efficacy of standard therapies may extend the survival of GBM patients. In this study, we investigated the role of KDM1A/LSD1 in DNA double strand break (DSB) repair and combination of KDM1A inhibitor and TMZ in vitro and in vivo using patient derived GSCs. Brain-bioavailability of the KDM1A inhibitor (NCD38) was established using LS-MS/MS. Effect of combination of KDM1A knockdown or inhibition with TMZ was studied using cell viability and self-renewal assays. Mechanistic studies were conducted using CUT&Tag-seq, RNA-seq, RT-qPCR, Western blot, HR and NHEJ reporter, immunofluorescence, and comet assays. Orthotopic murine models were used to study efficacy in vivo. TCGA analysis showed KDM1A is highly expressed in TMZ treated GBM patients. Knockdown or knockout or inhibition of KDM1A enhanced TMZ efficacy in reducing the viability and selfrenewal of GSCs. Pharmacokinetic studies established that NCD38 readily crosses the BBB. CUT&Tag-seq studies showed that KDM1A is enriched at the promoters of DNA repair genes and RNA-seq studies confirmed that KDM1A inhibition reduced their expression. Knockdown or inhibition of KDM1A attenuated HR and NHEJ-mediated DNA repair capacity and enhanced TMZ mediated DNA damage. Combination of KDM1A knockdown or inhibition and TMZ treatment significantly enhanced survival of tumor bearing mice. Our results provide evidence that KDM1A inhibition sensitizes GBM to TMZ via attenuation of DNA DSB repair pathways.

1 June 2016 in Brain Research Bulletin
Verified
Journal Article
Closed access
UPUday Pratap
Uday Pratap
APAnushree Patil
Anushree Patil
HSHimanshu R. Sharma
Himanshu R. Sharma
LHLalgi Hima
Lalgi Hima
RCRamanathan Chockalingam
Ramanathan Chockalingam
STSrinivasan ThyagaRajan
Srinivasan ThyagaRajan

Verified
Journal Article
Open access
PDF file
DBDarrell Brann
Darrell Brann
YLYujiao Lu
Yujiao Lu
JWJing Wang
Jing Wang
GSGangadhara R Sareddy
Gangadhara R Sareddy
UPUday Pratap
Uday Pratap
RVRatna Vadlamudi
Ratna Vadlamudi
In addition to being a steroid hormone, 17β-estradiol (E2) is also a neurosteroid produced in neurons in various regions of the brain of many species, including humans. Neuron-derived E2 (NDE2) is synthesized from androgen precursors via the action of the biosynthetic enzyme aromatase, which is located at synapses and in presynaptic terminals in neurons in both the male and female brain. In this review, we discuss evidence supporting a key role for NDE2 as a neuromodulator that regulates synaptic plasticity and memory. Evidence supporting an important neuromodulatory role of NDE2 in the brain has come from studies using aromatase inhibitors, aromatase overexpression in neurons, global aromatase knockout mice, and the recent development of conditional forebrain neuron-specific knockout mice. Collectively, these studies demonstrate a key role of NDE2 in the regulation of synapse and spine density, efficacy of excitatory synaptic transmission and long-term potentiation, and regulation of hippocampal-dependent recognition memory, spatial reference memory, and contextual fear memory. NDE2 is suggested to achieve these effects through estrogen receptor-mediated regulation of rapid kinase signaling and CREB-BDNF signaling pathways, which regulate actin remodeling, as well as transcription, translation, and transport of synaptic proteins critical for synaptic plasticity and function.

1 December 2015 in International Immunopharmacology
Verified
Journal Article
Closed access
UPUday Pratap
Uday Pratap
HSHimanshu R. Sharma
Himanshu R. Sharma
AMAparna Mohanty
Aparna Mohanty
PKPrathamesh Kale
Prathamesh Kale
SGSrinivasan Gopinath
Srinivasan Gopinath
STSrinivasan ThyagaRajan
Srinivasan ThyagaRajan